Patient Profile & Mechanism of Action (MOA)
Are your patients telling you it’s time for something else?1-4
Up to 40% of patients receiving a TNFi + cDMARD therapy do not achieve ACR20 response in clinical trials. After a TNFi option fails, does finding the next step feel like a guessing game?
Consider the story of Anna, an established patient who takes a TNFi + cDMARD therapy for her moderately to severely active RA.
Given Anna's experience with her current TNFi + cDMARD therapy, is it time to reach for Olumiant?
Olumiant is a JAK inhibitor for the treatment of moderately to severely active RA1
How does Olumiant work?
- Within the intracellular signaling pathway, JAKs phosphorylate and activate STATs, which modulate gene expression within the cell
- Olumiant modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs
- Within in vitro assays, Olumiant has greater inhibitory potency at JAK1, JAK2, and TYK2, relative to JAK3
The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.